Interpreting Outcomes of Chronic Total Occlusion Revascularization Strategies Authors: Ahmet Güner, Ezgi Gültekin Güner, Fatih Uzun Published: 2026 We read with great interest the Gulf Chronic Total Occlusion (CTO) Registry by Daoulah et al1, which provides important contemporary data comparing medical therapy, percutaneous coronary intervention (PCI), and coronary artery bypass grafting (CABG) in patients with CTO. The authors are to be commended for the application of inverse probability of treatment weighting, doubly robust estimation, and restricted mean survival time analyses in a large, clinically heterogeneous cohort. Nevertheless, several methodological considerations merit attention before interpreting the reported absence of significant differences in cardiovascular outcomes across treatment strategies. First, confounding by indication remains the principal limitation. The treatment groups represented fundamentally distinct clinical and anatomical phenotypes. Patients managed medically exhibited worse renal function, lower left ventricular ejection fraction, and a higher prevalence of cardiogenic shock despite less complex CTO anatomy, whereas those undergoing CABG predominantly had extensive multivessel coronary artery disease, and PCI patients demonstrated greater lesion-specific complexity. Although inverse probability of treatment weighting improved covariate balance, 6 of 30 variables in the CABG vs medical therapy comparison retained standardized mean differences between 0.10 and 0.20.1 More importantly, no statistical adjustment can fully account for unmeasured confounders, including frailty, ischemic burden, myocardial viability, anatomical suitability, patient preference, and Heart Team decision-making. Accordingly, the reported estimates should be interpreted as associative rather than causal. Second, the absence of statistical significance should not be equated with equivalence of treatment strategies. The study reported only 55 in-hospital major adverse cardiovascular events, yielding limited statistical power (approximately 35%) to detect a 5% absolute risk difference.1 Consequently, wide CIs allow for the possibility of clinically meaningful benefit or harm. This limitation extends to long-term outcomes, where at 36 months PCI vs medical therapy demonstrated a restricted mean survival time difference of −1.31 months (95% CI: -2.64 to +0.02; P = 0.053).1 These findings indicate a failure to demonstrate superiority rather than evidence of therapeutic equivalence. Third, interpretation of CTO-PCI outcomes requires caution given the reported technical success rate of 77.8%. An intention-to-treat analysis that combines successful and failed PCI procedures may attenuate potential benefits of successful revascularization while incorporating procedural risks associated with unsuccessful attempts. A landmark or stratified analysis comparing successful PCI, failed PCI, and medical therapy could provide additional mechanistic insight, although such approaches would introduce further selection bias. Lastly, conclusions regarding symptomatic benefit remain limited in the absence of systematic assessment of baseline and follow-up patient-reported outcomes. Although adjusted Canadian Cardiovascular Society class I prevalence favored CABG, the registry lacked standardized baseline angina assessment and validated quality-of-life instruments, as acknowledged by the authors. Footnotes The authors have reported that they have no relationships relevant to the contents of this paper to disclose. The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center. Reference